📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Loading analysis...
Acutaas Chemicals Recommends Final Dividend of Rs 2.5 Per Share for FY 2025-26
The Board of Directors of Acutaas Chemicals Limited has recommended a final dividend of Rs 2.5 per equity share for the financial year 2025-26. This represents a 50% payout on the face value of Rs 5 per share. The dividend will be distributed across 8,18,71,122 equity shares, pending approval from shareholders at the upcoming 19th Annual General Meeting. Record and payout dates will be announced by the company in due course.
Key Highlights
Recommended a final dividend of Rs 2.5 per equity share for FY 2025-26
Dividend rate stands at 50% of the face value of Rs 5 per share
Total number of eligible equity shares is 8,18,71,122
Subject to shareholder confirmation at the 19th Annual General Meeting
💼 Action for Investors
Investors should hold the stock to be eligible for the dividend and watch for the announcement of the record date. The 50% dividend payout reflects a positive return to shareholders for the fiscal year.
Loading analysis...
Acutaas Chemicals FY26 PAT Surges 122% to ₹3,564 Mn; Q4 Margins Hit Record 31%
Acutaas Chemicals (formerly Ami Organics) delivered exceptional FY26 results, with annual revenue rising 33% to ₹13,394 million. Net profit for the year surged 122% to ₹3,564 million, supported by a massive expansion in EBITDA margins to 35.9%. The company achieved its highest-ever quarterly PAT margin of 31% in Q4 FY26, driven by strong growth in the Pharma CDMO and Semiconductor businesses. Management has guided for a robust 25% revenue growth in FY27, focusing on high-growth verticals like battery chemicals.
Key Highlights
FY26 Revenue grew 33% YoY to ₹13,394 million, led by a 37.5% jump in Advance Intermediates.
Annual PAT surged 122.2% to ₹3,564 million, while Q4 PAT rose 114.1% YoY to ₹1,343 million.
EBITDA margins expanded significantly from 23.0% in FY25 to 35.9% in FY26.
Return on Equity (ROE) jumped to 32.5% in FY26 compared to 15.1% in the previous year.
Management provided a strong growth outlook of 25% revenue increase for FY27.
💼 Action for Investors
The company demonstrates industry-leading margin expansion and high return ratios (ROCE of 39.3%). Investors should monitor the execution of the 25% growth guidance for FY27 as a key performance indicator.
Loading analysis...
Acutaas Chemicals Q4 PAT Surges 114% YoY to ₹1,343 Mn; FY27 Revenue Guidance at 25%
Acutaas Chemicals reported a stellar performance for Q4 FY26, with revenue growing 40.3% YoY to ₹4,328 million. Net profit (PAT) more than doubled, rising 114.1% YoY to ₹1,343 million, driven by significant margin expansion. EBITDA margins improved drastically to 42.4% from 27.5% in the previous year's quarter. For the full year FY26, the company achieved a PAT of ₹3,564 million, a 122.2% increase over FY25. Management has provided a confident outlook, guiding for 25% revenue growth in FY27.
Key Highlights
Q4 FY26 Revenue from operations grew 40.3% YoY to ₹4,328 million
Q4 PAT jumped 114.1% YoY to ₹1,343 million with record margins of 31.0%
EBITDA for the quarter rose 116% YoY to ₹1,835 million, with margins expanding to 42.4%
Full-year FY26 PAT reached ₹3,564 million, marking a 122.2% growth over FY25
Management guided for 25% revenue growth in FY27, focusing on Battery Chemicals and Semiconductors
💼 Action for Investors
Investors should consider the stock's strong momentum and margin expansion as a sign of successful diversification into high-value sectors. The 25% growth guidance for FY27 provides clear visibility for future earnings and justifies a positive outlook.
Loading analysis...
Acutaas Chemicals Recommends Rs 2.50 Dividend; Indichem INC Named Material Subsidiary
Acutaas Chemicals Limited (formerly Ami Organics) has approved its audited financial results for the fiscal year ended March 31, 2026. The Board recommended a final dividend of Rs 2.50 per equity share (50% of face value), pending shareholder approval. A significant development is the classification of step-down subsidiary Indichem INC as a 'Material Subsidiary' based on its financial performance. The company also refreshed its audit team by appointing new internal and cost auditors for the 2026-27 fiscal year.
Key Highlights
Recommended a final dividend of Rs 2.50 per equity share of Rs 5 face value (50% payout).
Dividend to be distributed across 8,18,71,122 equity shares subject to AGM approval.
Indichem INC identified as a Material Subsidiary, indicating a significant contribution to consolidated financials.
M/s K. C Mehta & Co. LLP appointed as Internal Auditors for the financial year 2026-27.
Audited Standalone and Consolidated Financial Results for FY 2025-26 approved by the Board.
💼 Action for Investors
Investors should note the dividend yield and the growing importance of the US-based subsidiary Indichem INC. Monitor the full financial statement for specific revenue and profit growth figures compared to the previous year.
Loading analysis...
Acutaas Chemicals Completes 75% Acquisition of South Korean Semiconductor Chemical Firm Indichem
Acutaas Chemicals, through its wholly owned subsidiary Acutaas Advance Material Limited, has completed the acquisition of a 75% controlling stake in South Korean firm Indichem Inc. Indichem is a newly incorporated entity specializing in the semiconductor chemicals industry, providing Acutaas with a strategic entry into this high-growth global market. The acquisition involved 300,000 shares at a par value of KRW 500 each plus a share premium. Indichem is currently constructing a manufacturing plant in South Korea, which is scheduled for commissioning by the end of the 2025 calendar year.
Key Highlights
Acquired 75% controlling stake (300,000 shares) in South Korean firm Indichem Inc.
Target entity operates in the specialized semiconductor chemicals industry.
Acquisition price set at KRW 500 per share par value plus applicable share premium.
Manufacturing plant in South Korea is slated for commissioning by the end of 2025.
Indichem Inc. now becomes a step-down subsidiary of Acutaas Chemicals Limited.
💼 Action for Investors
This acquisition is a strategic move into the high-margin semiconductor value chain. Investors should monitor the timely commissioning of the South Korean facility by late 2025 as it will be the primary driver for revenue from this new segment.
Loading analysis...
Acutaas Chemicals Q3 FY26 PAT Jumps 133.7% to ₹106.2 Cr; Revenue Guidance Raised to 30%
Acutaas Chemicals reported a stellar Q3 FY26 with revenue growing 43% YoY to ₹393.2 crores, driven by a 47% surge in the Advanced Pharma Intermediates segment. The company achieved its highest-ever margins, with EBITDA margins expanding significantly to 38.3% due to a favorable product mix and operating leverage. Management has upgraded its full-year FY26 revenue growth guidance to 30% and EBITDA margin guidance to a range of 32-35%. Strategic expansions into battery and semiconductor chemicals are progressing, with a new battery chemicals block inaugurated in January 2026.
Key Highlights
Revenue from operations grew 43% YoY to ₹393.2 crores in Q3 FY26.
PAT crossed the ₹100 crore milestone, reaching ₹106.2 crores, a 133.7% YoY increase.
EBITDA margins expanded by 1,335 bps YoY to 38.3%, leading to an upgraded annual margin guidance of 32-35%.
Pharma Intermediates segment revenue rose 47% YoY to ₹351.1 crores, fueled by CDMO growth.
Inaugurated a new battery chemicals block at Jhagadia; commercial operations expected to ramp up from Q1 FY27.
💼 Action for Investors
Investors should view the guidance upgrade and margin expansion as strong indicators of structural growth and improved product mix. The entry into high-growth battery and semiconductor chemical segments provides a long-term catalyst for valuation re-rating.
Loading analysis...
Acutaas Chemicals Reports FY25 Revenue of ₹9,898 Million and 25% Capacity Expansion
Acutaas Chemicals Limited, formerly known as Ami Organics, has released its Annual Sustainability Report for FY 2024-25, reporting a standalone revenue of ₹9,898 million. The company achieved a significant 25% increase in production capacity, primarily driven by its Ankleshwar facility. Strategically, the firm is expanding into high-value sectors including semiconductor-grade chemistries and battery materials. On the ESG front, it earned the EcoVadis Platinum Medal, placing it in the top 1% of companies globally, and operationalized 15.8 MW of solar capacity.
Key Highlights
Standalone revenue reached ₹9,898 million with consolidated revenue surpassing ₹1,000 crore
Production capacity increased by 25% during the fiscal year, led by the Ankleshwar unit
Achieved EcoVadis Platinum Medal and operationalized 15.8 MW of solar power capacity
Portfolio expanded to over 610 chemistries with exports to more than 55 countries
Zero conflict-of-interest cases and zero POSH complaints reported for the year
💼 Action for Investors
Investors should note the company's successful transition to its new identity and its strong ESG positioning which may attract institutional capital. The 25% capacity expansion and move into semiconductor chemicals provide a positive outlook for medium-term growth.
Loading analysis...
Acutaas Chemicals Q3 FY26 Net Profit Surges 139% YoY to ₹108.6 Cr; Revenue Up 42%
Acutaas Chemicals (formerly Ami Organics) reported a stellar performance for Q3 FY26, with consolidated revenue growing 42.3% YoY to ₹391.2 crore. Net profit for the quarter witnessed a massive jump of 139% YoY, reaching ₹108.6 crore compared to ₹45.4 crore in the previous year. For the nine-month period, the company has already surpassed its full-year FY25 profit, recording ₹222.1 crore. The company also highlighted a strategic investment of ₹130.80 crore in its South Korean joint venture, Indichem Inc., to bolster its specialty chemicals portfolio.
Key Highlights
Consolidated Revenue from operations rose 42.3% YoY to ₹39,118.33 Lakhs in Q3 FY26.
Net Profit surged by 139% YoY to ₹10,863.62 Lakhs, driven by strong operational efficiency.
Basic EPS for the quarter stood at ₹13.12, up from ₹5.42 in the corresponding quarter of the previous year.
The company invested ₹130.80 crore in South Korean JV Indichem Inc., holding a 75% stake through its subsidiary.
9-month consolidated profit reached ₹22,208.56 Lakhs, a 127% increase over the ₹9,770.16 Lakhs recorded in 9M FY25.
💼 Action for Investors
The company is exhibiting robust earnings momentum and successful execution of its global expansion strategy. Investors should maintain a positive outlook while monitoring the integration of the South Korean JV and the impact of the newly granted ESOPs on future employee costs.
Loading analysis...
Acutaas Chemicals Q3 FY26 PAT Surges 133.7% YoY to ₹1,062 Mn; Revenue Up 43%
Acutaas Chemicals reported a stellar performance for Q3 FY26, with revenue growing 43% YoY to ₹3,932 million. The company achieved a significant milestone as quarterly PAT crossed ₹1,000 million for the first time, reaching ₹1,062 million. Profitability margins saw substantial expansion, with EBITDA margins jumping to 38.3% from 25.0% in the previous year. Management has also raised its full-year revenue growth guidance from 25% to approximately 30%, citing strong momentum in the CDMO business and upcoming verticals like battery and semiconductor chemicals.
Key Highlights
Revenue from operations grew 43% YoY to ₹3,932 million, driven by the CDMO business ramp-up.
Net Profit (PAT) skyrocketed by 133.7% YoY to ₹1,062 million, crossing the ₹1,000 million quarterly milestone.
EBITDA margins expanded significantly by 1,330 bps YoY to reach 38.3% compared to 25.0% in Q3FY25.
Full-year revenue growth guidance revised upward from 25% to approximately 30% for FY26.
Gross margins improved to 57.0%, up 1,073 bps YoY, reflecting a superior product mix and operational efficiency.
💼 Action for Investors
Investors should take note of the significant margin expansion and the management's confidence reflected in the upward guidance revision. The company's strategic pivot into semiconductor and battery chemicals offers strong long-term growth catalysts beyond its core pharmaceutical business.
Loading analysis...
Acutaas Chemicals Q3 FY26 PAT Surges 133.7% YoY to ₹1,062 Mn; Revenue Guidance Raised to 30%
Acutaas Chemicals reported a stellar Q3 FY26 performance with revenue growing 43% YoY to ₹3,932 million, driven by a robust ramp-up in the CDMO business. Profitability saw a massive jump as EBITDA rose 119.4% to ₹1,507 million, with margins expanding significantly to 38.3% due to favorable product mix and operating leverage. Consequently, PAT grew by 133.7% YoY to reach ₹1,062 million, the highest ever for the company. Management has revised its full-year revenue growth guidance upward to approximately 30% based on a strong order book and improved visibility.
Key Highlights
Revenue from operations grew 43% YoY to ₹3,932 million in Q3 FY26.
EBITDA margins expanded by 1,330 bps YoY to 38.3%, leading to EBITDA of ₹1,507 million.
Net Profit (PAT) increased by 133.7% YoY to ₹1,062 million with a 27% margin.
Management raised FY26 revenue growth guidance from 25% to approximately 30%.
Advanced Intermediates segment remains the primary driver, contributing ₹3,511 million to revenue.
💼 Action for Investors
Investors should view the significant margin expansion and guidance upgrade as a strong bullish signal. The company's strategic pivot into high-growth battery and semiconductor chemicals provides a long-term growth runway.
Loading analysis...
Acutaas Chemicals Reports Q3 FY26 Results; Auditor Issues Clean Review Report
Acutaas Chemicals Limited, formerly known as Ami Organics Limited, has submitted its standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The independent auditor, Maheshwari & Co., has issued a clean review report, indicating no material misstatements in the financial statements. The consolidated results encompass various subsidiaries including Acutaas Chemicals Electrolytes and Acutaas Advance Material, as well as joint ventures. This filing confirms the company's adherence to SEBI's regulatory reporting requirements.
Key Highlights
Acutaas Chemicals (formerly Ami Organics) filed financial results for the period ended December 31, 2025.
Independent Auditor Maheshwari & Co. issued an unmodified review report for both standalone and consolidated financials.
The consolidated entity includes subsidiaries such as Baba Fine Chemicals and step-down subsidiaries like Indichem Inc.
Financial statements were prepared in accordance with Ind AS 34 (Interim Financial Reporting) and SEBI Regulation 33.
The board meeting for the approval of these results was concluded on January 28, 2026.
💼 Action for Investors
Investors should review the detailed profit and loss statements once fully published to assess revenue and margin performance. The clean audit report provides confidence in the company's financial reporting integrity.
Loading analysis...
Acutaas Chemicals Inaugurates Phase 1 Battery Chemicals Block at Jhagadia Facility
Acutaas Chemicals Limited has officially inaugurated Phase 1 of its new state-of-the-art manufacturing block at the Unit-III Jhagadia facility in Gujarat. This dedicated facility will focus on producing electrolyte additives and other battery chemicals, marking a significant expansion into the high-growth EV supply chain. The inauguration took place on January 19, 2026, following an initial project intimation in December 2024. This move aligns with the company's strategy to diversify its specialty chemical portfolio into the energy storage sector.
Key Highlights
Inauguration of Phase 1 of a dedicated manufacturing block for electrolyte additives and battery chemicals.
The facility is located at the existing Unit-III Jhagadia site at Plot No. 910/1/B, G.I.D.C., Gujarat.
The expansion follows through on the company's strategic plan initiated on December 11, 2024.
The new block is described as a 'State of the Art' facility targeting the specialized battery materials market.
💼 Action for Investors
Investors should view this as a positive development for long-term growth in the specialty chemicals space. Monitor the ramp-up of production and the subsequent impact on revenue and margins in the upcoming fiscal quarters.